McKesson agreed to acquire Precision Medicine Group in a deal valued at about $2.25 billion, strengthening its oncology and clinical research services footprint. Precision Medicine Group contributes biomarker intelligence, laboratory services, global clinical research organization support, market access consulting, and commercialization support—capabilities designed to help sponsors across the development-to-launch lifecycle. The acquisition reflects a broader industry move toward integrated, tech-enabled execution for biopharma clients, including services that reduce the operational burden of clinical trials and commercialization. By folding Precision into McKesson’s Oncology & Multispecialty segment, the buyer positions itself as a one-stop partner for precision medicine programs.